Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000317685 | SCV000329113 | pathogenic | not provided | 2022-05-18 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 28232778, 26786923, 29625052, 26689913, 17407155) |
Labcorp Genetics |
RCV000034893 | SCV000543350 | pathogenic | Bloom syndrome | 2024-01-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln700*) in the BLM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). This variant is present in population databases (rs367543028, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with Bloom syndrome (PMID: 17407155). ClinVar contains an entry for this variant (Variation ID: 42067). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000034893 | SCV000916688 | pathogenic | Bloom syndrome | 2018-09-14 | criteria provided, single submitter | clinical testing | Variant summary: BLM c.2098C>T (p.Gln700X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.2207_2212delinsTAGATTC (p.Tyr736fsX5) and c.2695C>T (p.Arg899X)). The variant allele was found at a frequency of 1.1e-05 in 277168 control chromosomes (gnomAD). c.2098C>T has been reported in the literature, in homozygosity or compound heterozygosity, in multiple individuals affected with Bloom Syndrome (German_2007). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating the variant impact. The most pronounced variant effect in homozygous individuals resulted in <20% mRNA amount compared to normal, based on Northern blot analyses (German_2007). Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Ambry Genetics | RCV001014425 | SCV001175127 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-10-20 | criteria provided, single submitter | clinical testing | The p.Q700* pathogenic mutation (also known as c.2098C>T), located in coding exon 8 of the BLM gene, results from a C to T substitution at nucleotide position 2098. This changes the amino acid from a glutamine to a stop codon within coding exon 8. This alteration has been reported in both a homozygous and compound heterozygous state in multiple individuals with Bloom syndrome (German J et al. Hum. Mutat., 2007 Aug;28:743-53). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Revvity Omics, |
RCV000034893 | SCV002018440 | pathogenic | Bloom syndrome | 2022-03-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000034893 | SCV004210893 | pathogenic | Bloom syndrome | 2024-03-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000034893 | SCV000485410 | pathogenic | Bloom syndrome | 2015-12-07 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000034893 | SCV002088031 | pathogenic | Bloom syndrome | 2017-03-16 | no assertion criteria provided | clinical testing |